Document is current
Any future updates will be listed below
-
Authors
Gan, Hui K. https://orcid.org/0000-0001-7319-8546
Parakh, Sagun
Lee, F. T.
Tebbutt, Niall C.
Ameratunga, Malaka
Lee, Sze Ting
O’Keefe, Graeme J.
Gong, Sylvia J.
Vanrenen, Christine
Caine, Jaren
Giovannetti, Mara
Murone, Carmel
Scott, Fiona E.
Guo, Nancy
Burvenich, Ingrid J. G.
Paine, Cameron
Macri, Mary J.
Kotsuma, Masakatsu
Senaldi, Giorgio
Venhaus, Ralph
Scott, Andrew M.
-
Funding
Funding for this research was provided by:
Daiichi-Sankyo
National Health and Medical Research Council
La Trobe University
Ludwig Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 14 December 2021
Accepted: 15 March 2022
First Online: 11 April 2022
Declarations
:
: This study was approved by the Institutional Ethics Committee (IEC) at Austin Health. Written informed consent was obtained from all patients and all methods were performed in accordance with the protocol-specified guidelines and regulations.
: No identifiable data or material in relation to individual patients is used in this publication. Informed consent was obtained from all individual participants included in the study.
: This study was approved by the Institutional Ethics Committee (IEC) at Austin Health. The study was conducted in accordance with the principles of the Declaration of Helsinki (fourth revision, 1996) and the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines.
: Consent to participate; Written informed consent was obtained from all patients and all methods were performed in accordance with the protocol-specified guidelines and regulations. Consent for publication: No identifiable data or material in relation to individual patients is used in this publication. Informed consent was obtained from all individual participants included in the study.
: Not applicable. HG received honoraria, travel support and/or research funding from AbbVie, Bristol-Myers Squibb, Eisai, EMD Serono and MSD. SP: received honoraria from AstraZeneca and MSD. NT serves as a consultant to Roche, Amgen, Bristol-Myers Squibb and Eisai Pharmaceuticals. MK and GS are employees of Daiichi Sankyo and may own stock. AMS received research funding and travel support from AbbVie; received research funding from Daiichi-Sankyo, EMD Serono, Merck, Telix, Avid, Celgene, ITM, Adalta; is a consultant and has stock in Life Science Pharmaceuticals, and has stock in Paracrine Therapeutics.
